

Financial news for PCRX dated on 2020-06-01: Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

Financial news for PCRX dated on 2020-05-27: Benzinga's Top Upgrades, Downgrades For May 27, 2020

Financial news for PCRX dated on 2020-05-27: Guggenheim Initiates Coverage On Pacira BioSciences with Neutral Rating

Financial news for PCRX dated on 2020-05-08: Stifel Maintains Hold on Pacira BioSciences, Lowers Price Target to \$48

Financial news for PCRX dated on 2020-05-08: SVB Leerink Maintains Outperform on Pacira BioSciences, Raises Price Target to \$45

Financial news for PCRX dated on 2020-05-07: Pacira BioSciences Q1 EPS \$0.530 Beats \$0.320 Estimate, Sales \$105.684M Beat \$102.970M Estimate

Financial news for PCRX dated on 2020-05-07: Pacira BioSciences Q1 EPS \$0.530 Beats \$0.320 Estimate, Sales \$105.700M Beat \$102.970M Estimate

Financial news for PCRX dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for PCRX dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for PCRX dated on 2020-04-30: Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to \$52

Financial news for PCRX dated on 2020-04-07: Pacira BioSciences shares are trading higher after Northland Capital Markets initiated coverage on the stock with an Outperform market and announced a price target of \$50 per share.

Financial news for PCRX dated on 2020-04-07: Northland Capital Markets Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target to \$50

Financial news for PCRX dated on 2020-04-07: Shares of several healthcare companies are trading higher amid optimism that coronavirus cases in Asia are potentially easing. Global slowing cases could raise hopes of a sooner return to spending and economic activity. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic.

Financial news for PCRX dated on 2020-03-24: The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test

Financial news for PCRX dated on 2020-03-20: Benzinga's Top Upgrades, Downgrades For March 20, 2020

Financial news for PCRX dated on 2020-03-20: SVB Leerink Upgrades Pacira BioSciences to Outperform, Lowers Price Target to \$44

Financial news for PCRX dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for PCRX dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for PCRX dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for PCRX dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for PCRX dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for PCRX dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for PCRX dated on 2020-02-24: HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Raises Price Target to \$63

Financial news for PCRX dated on 2020-02-20: Pacira BioSciences Q4 Adj. EPS \$0.56

Beats \$0.44 Estimate, Sales \$122.424M Beat \$121.28M Estimate

Financial news for PCRX dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for PCRX dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for PCRX dated on 2020-02-11: Stocks That Hit 52-Week Highs On Tuesday

Financial news for PCRX dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for PCRX dated on 2020-01-24: SunTrust Robinson Humphrey Initiates Coverage On Pacira BioSciences with Buy Rating, Announces \$60 Price Target

Financial news for PCRX dated on 2020-01-23: Pacira Biosciences Shares Unaffected After Hours As Hearing SunTrust Initiated Stock With Buy Rating, \$60 Price Target

Financial news for PCRX dated on 2020-01-09: Pacira Biosciences Sees FY19 Sales \$421M vs \$418.1M Estimate

Financial news for PCRX dated on 2020-01-07: EXPAREL Achieves Primary And Key Secondary Endpoints In Phase 4 CHOICE Study In Cesarean Section Patients

Financial news for PCRX dated on 2019-12-17: Pacira BioSciences Announces Results From Phase 3 PLAY Study Of EXPAREL In Pediatric Patients; Says Findings Were Consistent With Overall Safety Profiles For Adult Patients With No Safety Concerns Identified

Financial news for PCRX dated on 2019-11-07: Pacira BioSciences Reiterated FY19 Exparel Sales \$400M - \$410M & Iovera Sales \$8M - 10M

Financial news for PCRX dated on 2019-11-07: Pacira BioSciences Q3 EPS \$0.48 Beats \$0.33 Estimate, Sales \$104.685M Miss \$104.89M Estimate

Financial news for PCRX dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for PCRX dated on 2019-11-06: Benzinga's Top Upgrades, Downgrades For November 6, 2019

Financial news for PCRX dated on 2019-11-06: BTIG Research Initiates Coverage On Pacira BioSciences with Buy Rating, Announces \$56 Price Target

Financial news for PCRX dated on 2019-09-26: 55 Biggest Movers From Yesterday

Financial news for PCRX dated on 2019-09-25: 34 Stocks Moving In Wednesday's Mid-Day Session

Financial news for PCRX dated on 2019-09-25: Pacira BioSciences Trades Higher After Joining S&P SmallCap 600

Financial news for PCRX dated on 2019-09-25: 23 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for PCRX dated on 2019-09-25: 24 Stocks Moving in Wednesday's Pre-Market Session

Financial news for PCRX dated on 2019-09-25: Pacira BioSciences shares are trading higher after the stock was added to the S&P SmallCap 600 index.

Financial news for PCRX dated on 2019-09-25: The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug

Financial news for PCRX dated on 2019-09-24: S&P Dow Jones Announces Pacira BioSciences Set to Join S&P SmallCap 600, Will Replace Butterfly

Financial news for PCRX dated on 2019-09-17: Pacira BioSciences Reports Completed Enrollment In Multicenter Registration Study Of EXPAREL In Pediatric Patients

Financial news for PCRX dated on 2019-08-08: Pacira BioSciences Guides FY19 Exparel Net Product Sales Of \$400M-\$410M; Guides FY19 Iovera Net Product Sales Of \$8M-\$10M

Financial news for PCRX dated on 2019-08-08: Pacira BioSciences Q2 EPS \$0.41 Beats \$0.34 Estimate, Sales \$102.6M Beat \$100.52M Estimate

Financial news for PCRX dated on 2019-08-08: The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Financial news for PCRX dated on 2019-07-29: 40 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for PCRX dated on 2019-07-10: Pacira BioSciences 13D Shows Consonance Capital Management Holds 6.8% Stake In Co.; Firm Had Previously Held 7.8% Stake

Financial news for PCRX dated on 2019-06-26: Pacira BioSciences Says New Retrospective Analysis Shows EXPAREL Is Associated With Significantly Less Opioid Use Following Third Molar Extraction

Financial news for PCRX dated on 2019-06-25: Pacira BioSciences Announces Validation Of EXPAREL Marketing Authorization Application From European Medicines Agency

Financial news for PCRX dated on 2019-06-19: Pacira BioSciences Names Max Reinhardt Pres

Financial news for PCRX dated on 2019-06-12: Pacira BioSciences Highlights New Data Showing Use Of EXPAREL Was Associated With Improved Clinical And Economic Outcomes Following Hip Replacement Surgery

Financial news for PCRX dated on 2019-06-11: Barclays Initiates Coverage On Pacira BioSciences with Overweight Rating, Announces \$52 Price Target

Financial news for PCRX dated on 2019-06-04: Pacira Highlights Publication Of EXPAREL Pivotal Study As Single-Dose Interscalene Brachial Plexus Nerve Block in Patients Undergoing Shoulder Surgery In 'Pain Medicine'

Financial news for PCRX dated on 2019-05-06: Mizuho Upgrades Pacira Pharmaceuticals, Inc. - Common Stock to Neutral, Raises Price Target to \$38

Financial news for PCRX dated on 2019-05-02: Pacira Shares Spike Above \$47 Level On Heavy Volume; Hearing Stifel Upgraded Stock In Mid-Day Call

Financial news for PCRX dated on 2019-05-02: Pacira BioSciences Sees FY19 EXPAREL Sales \$400M-\$410M

Financial news for PCRX dated on 2019-05-02: Pacira Pharmaceuticals Q1 EPS \$0.22 Misses \$0.26 Estimate, Sales \$91.313M Miss \$92.1M Estimate

Financial news for PCRX dated on 2019-05-02: The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

Financial news for PCRX dated on 2019-05-02: 60 Biggest Movers From Yesterday

Financial news for PCRX dated on 2019-05-01: 46 Stocks Moving In Wednesday's Mid-Day Session

Financial news for PCRX dated on 2019-05-01: Pacira BioSciences shares are trading higher after competitor Heron Therapeutics' marketing application for a pain treatment was rejected by the FDA.

Financial news for PCRX dated on 2019-05-01: Pacira Biosciences Shares Spike ~12% Premarket Following Complete Response Letter From Heron Therapeutics For Its Postoperative Pain Treatment; BZ NOTE: Pacira Has A Competing Drug Candidate

Financial news for PCRX dated on 2019-03-13: Pacira Highlights EXPAREL Data

Financial news for PCRX dated on 2019-03-05: Pacira To Acquire MyoScience, Adding FDA-approved Ioverao System For Non-Opioid Pain Control

Financial news for PCRX dated on 2019-02-28: 51 Stocks Moving In Thursday's Mid-Day Session

Financial news for PCRX dated on 2019-02-28: Pacira Pharmaceuticals Q4 EPS \$0.47 Beats \$0.28 Estimate, Sales \$95.1M Beat \$93.69M Estimate

Financial news for PCRX dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for PCRX dated on 2019-02-12: Pacira Announces Start Of Commercial Production At New EXPAREL Facility, expected To Double Co.'s Manufacturing Capacity

Financial news for PCRX dated on 2019-02-01: Mizuho Downgrades Pacira Pharmaceuticals to Underperform

Financial news for PCRX dated on 2019-01-16: Pacira Pharmaceuticals, Inc. Reports Its

Phase 4 Study Of EXPAREL Achieved Primary Endpoint, Showed Statistically Significant Reductions In Opioid Consumption And Pain Scores In C-Section Patients

Financial news for PCRX dated on 2019-01-03: Pacira Reports Preliminary 2018 Net EXPAREL Sales Of \$331M And Q4 Net EXPAREL Sales Of \$94M

Financial news for PCRX dated on 2019-01-03: Pacira Reports Prelim. 2018 Net EXPAREL Sales Of \$331M

Financial news for PCRX dated on 2018-12-12: Pacira Pharmaceuticals Highlights Publication Of Data Showing Reductions In Postsurgical Pain And Opioid Requirements With EXPAREL In Cesarean Section Patients

Financial news for PCRX dated on 2018-11-16: Pacira Pharmaceuticals CMO Presents At FDA Advisory Committee Meeting Focused On Assessment Of Opioid-Sparing Outcomes In Clinical Trials

Financial news for PCRX dated on 2018-11-02: UPDATE: Pacira Says Product-Specific C-Code For Ambulatory Surgical Center Procedures, D-Code For Dental Procedures To Take Effect Jan. 1, 2019

Financial news for PCRX dated on 2018-11-02: UPDATE: Pacira Pharma Says New Reimbursement Model Will Provide Payemtn For EXPAREL At Average Sales Price +6%

Financial news for PCRX dated on 2018-11-02: Pacira Pharma Reports Centers For Medicare, Medicaid Services, American Dental Association Have Established New Reimbursement for EXPAREL

Financial news for PCRX dated on 2018-11-02: JP Morgan Maintains Neutral on Pacira Pharmaceuticals, Raises Price Target to \$50

Financial news for PCRX dated on 2018-11-02: BMO Capital Maintains Market Perform on Pacira Pharmaceuticals, Raises Price Target to \$47

Financial news for PCRX dated on 2018-11-01: Pacira Pharmaceuticals Raises FY2018 Sales Guidance from \$300.0M-310.0M to \$325.0M-330.0M vs \$326.84M Est

Financial news for PCRX dated on 2018-11-01: Pacira Pharmaceuticals, Inc. Q3 EPS \$0.31 Beats \$0.08 Estimate, Sales \$83.448M Beat \$80.18M Estimate

Financial news for PCRX dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for PCRX dated on 2018-10-30: Aetna To Offer Expanded Coverage For Pacira Pharmaceuticals' EXPAREL In Select Ambulatory Surgical Centers

Financial news for PCRX dated on 2018-10-30: Aetna To Offer Expanded Coverage For Its Exparel In Select Ambulatory Surgical Centers, Will Reimburse For Use In Florida, New Jersey

Financial news for PCRX dated on 2018-10-22: Pacira Pharmaceuticals 13D Shows Consonance Capital Management Cut Stake From ~3.75M Shares To ~3.65M Shares

Financial news for PCRX dated on 2018-10-09: FDA Commissioner Scott Gottlieb Issues Statement On 'new efforts to advance the development of generic copies of complex drugs to improve patient access to medicines'

Financial news for PCRX dated on 2018-09-20: Stocks Which Set New 52-Week High Yesterday, September 19th

Financial news for PCRX dated on 2018-09-20: The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut

Financial news for PCRX dated on 2018-09-14: Pacira Shares Look Expensive, Stifel Says In Bearish Initiation

Financial news for PCRX dated on 2018-09-14: Benzinga's Top Upgrades, Downgrades For September 14, 2018

Financial news for PCRX dated on 2018-09-14: Stifel Nicolaus Initiates Coverage On Pacira Pharmaceuticals with Sell Rating, Announces \$41 Price Target

Financial news for PCRX dated on 2018-08-17: Stocks Which Set New 52-Week High Yesterday, August 16th

Financial news for PCRX dated on 2018-08-16: Stocks Which Set New 52-Week High Yesterday, August 15th

Financial news for PCRX dated on 2018-08-16: The Daily Biotech Pulse: No Anxiety For

Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait

Financial news for PCRX dated on 2018-08-15: Stocks Which Set New 52-Week High Yesterday, August 14th

Financial news for PCRX dated on 2018-08-06: Benzinga's Top Upgrades, Downgrades For August 6, 2018

Financial news for PCRX dated on 2018-08-06: Barclays Maintains Overweight on Pacira Pharmaceuticals, Raises Price Target to \$50

Financial news for PCRX dated on 2018-08-06: Bank of America Downgrades Pacira Pharmaceuticals to Neutral

Financial news for PCRX dated on 2018-08-06: Wedbush Maintains Outperform on Pacira Pharmaceuticals, Raises Price Target to \$85

Financial news for PCRX dated on 2018-08-03: Benzinga's Top Upgrades, Downgrades For August 3, 2018

Financial news for PCRX dated on 2018-08-03: Needham Upgrades Pacira Pharmaceuticals to Buy

Financial news for PCRX dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for PCRX dated on 2018-08-02: Pacira Pharmaceuticals Q2 EPS \$0.24 Beats \$0.07 Estimate, Sales \$84.1M Beat \$78.86M Estimate

Financial news for PCRX dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for PCRX dated on 2018-07-10: Pacira Reports Prelim. Net EXPAREL Sales of \$80.4M for Q2, Up 15% YoY In Same Period

Financial news for PCRX dated on 2018-06-22: 56 Biggest Movers From Yesterday

Financial news for PCRX dated on 2018-06-20: Pacira Pharmaceuticals Option Alert: Jul 20 \$35 Puts at the Bid: 1000 @ \$1.0 vs 2277 OI; Earnings 8/1 Before Open [est] Ref=\$39.95

Financial news for PCRX dated on 2018-06-19: Pacira Pharmaceuticals, Nuance Biotech Report License Agreement for EXPAREL in China; Pacira Grants Nuance Rights To Develop And Commercialize EXPAREL In China For An Upfront Payment Of \$3m And Is Eligible For Milestone Payments Of \$55M

Financial news for PCRX dated on 2018-06-11: Pacira Pharmaceuticals Option Alert: Jul 20 \$37.5 Calls at the Ask: 1500 @ \$2.601 vs 157 OI; Earnings 8/1 Before Open [est] Ref=\$37.2

Financial news for PCRX dated on 2018-05-03: Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss

Financial news for PCRX dated on 2018-05-03: Pacira Pharmaceuticals Sees FY2018 EXPAREL Net Product Sales \$300.0M-310.0M

Financial news for PCRX dated on 2018-05-03: Pacira Pharmaceuticals Q1 EPS \$0.02 Beats \$0.01 Estimate, Sales \$74.607M Beat \$73.93M Estimate

Financial news for PCRX dated on 2018-04-09: Pacira On Friday Announced FDA Approval Of Supplemental New Drug Application For EXPAREL As Opioid-Free Nerve Block For Regional Analgesia

Financial news for PCRX dated on 2018-04-09: 30 Biggest Movers From Friday

Financial news for PCRX dated on 2018-04-06: Pacira Shares Spike to \$34.75, FDA.gov Site Shows Label Approval For EXPAREL

Financial news for PCRX dated on 2018-04-06: Pacira Pharma Shares Spike To High Of \$31.50 on Volume

Financial news for PCRX dated on 2018-04-06: REMINDER: Pacira Pharma Has PDUFA Date Today For EXPAREL sNDA

Financial news for PCRX dated on 2018-04-03: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for PCRX dated on 2018-04-03: 41 Biggest Movers From Yesterday

Financial news for PCRX dated on 2018-04-02: The Week Ahead: Switch's Lockup Expires, Spotify Debuts, And More

Financial news for PCRX dated on 2018-03-30: The Week Ahead In Biotech: PDUFA Dates, Clinical Trials And Conferences

Financial news for PCRX dated on 2018-02-28: Pacira Sees FY18 EXPAREL Net Product Sales Of \$300-\$310M

Financial news for PCRX dated on 2018-02-28: Pacira Reports Q4 EPS \$0.39 vs \$0.10 Est., Sales \$79.1M vs \$79.3M Est.

Financial news for PCRX dated on 2018-02-20: 45 Biggest Movers From Friday

Financial news for PCRX dated on 2018-02-16: Pacira Pharma Shares Down ~17% After FDA AdCom Didn't Recommend Approval of EXPAREL Thursday, Needham Downgraded Stock To Hold Earlier

Financial news for PCRX dated on 2018-02-16: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for PCRX dated on 2018-02-16: Needham Downgrades Pacira Pharmaceuticals to Hold

Financial news for PCRX dated on 2018-02-16: 32 Stocks Moving In Friday's Pre-Market Session

Financial news for PCRX dated on 2018-02-15: Pacira Pharma Shares Resume Trade, Down 16%

Financial news for PCRX dated on 2018-02-15: Pacira Pharmaceuticals To Resume Trade At 4:15pm

Financial news for PCRX dated on 2018-02-15: UPDATE: Pacira Says 4 Committee Members Voted To Recommend EXPAREL Approval, 6 Believes More Research Is Needed To Further Support New Indication

Financial news for PCRX dated on 2018-02-15: Pacira Pharma Offers Statement On FDA Panel For EXPAREL: Says Did Not Reach Unanimous Decision On Efficacy, Safety

Financial news for PCRX dated on 2018-02-15: REMINDER: Pacira Pharma Shares Remain Halted, As FDA AdCom Mtg. for EXPAREL Concludes Today

Financial news for PCRX dated on 2018-02-14: Pacira Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review sNDA for EXPAREL as a Nerve Block for Regional Analgesia, Anesthetic and Analgesic Drug Products Advisory Committee Meeting February 14-15

Financial news for PCRX dated on 2018-02-14: Pacira Pharmaceuticals Halted News Pending

Financial news for PCRX dated on 2018-02-12: The Week Ahead: Earnings, FDA Actions, And Industry Conferences To Watch

Financial news for PCRX dated on 2018-02-12: FDA Posts Briefing Documents for Advisory Meeting Reviewing sNDA for EXPAREL as a Nerve Block for Regional Analgesia, Adcom. meeting Scheduled For Feb. 14th-15th

Financial news for PCRX dated on 2018-01-31: Attention Biotech Investors: February PDUFA Catalysts Come Calling

Financial news for PCRX dated on 2018-01-19: Seaport Global Initiates Coverage On Pacira Pharmaceuticals with Buy Rating, Announces \$50.00 Price Target

Financial news for PCRX dated on 2018-01-04: Pacira Pharma Shares Down 7% Thurs. Following Earlier Q4 Guidance; Thurs. Morning Price Failed To Hold Over \$46 For Third Time Since End Of Nov.

Financial news for PCRX dated on 2018-01-04: Pacira Pharma Reports Prelim. Total Sales Figures: Q4 \$79.1M vs \$78.6M Est.; FY17 \$286.6M vs \$286M Est.

Financial news for PCRX dated on 2018-01-03: Benzinga's Top Upgrades, Downgrades For January 3, 2018

Financial news for PCRX dated on 2018-01-03: Leerink Swann Initiates Coverage On Pacira Pharmaceuticals with Market Perform Rating, Announces \$46.00 Price Target

Financial news for PCRX dated on 2017-12-18: Benzinga's Top Upgrades, Downgrades For December 18, 2017

Financial news for PCRX dated on 2017-12-18: JP Morgan Initiates Coverage On Pacira Pharmaceuticals with Neutral Rating, Announces \$47.00 Price Target

Financial news for PCRX dated on 2017-12-07: Pacira Names Dr. Scott Braunstein COO, Dr. Richard Scranton Chief Scientific Officer

Financial news for PCRX dated on 2017-11-29: Benzinga's Top Upgrades, Downgrades For November 29, 2017

Financial news for PCRX dated on 2017-11-29: Mizuho Downgrades Pacira Pharmaceuticals to Neutral

Financial news for PCRX dated on 2017-11-15: Pacira's Exparel sNDA To Be Reviewed By FDA Advisory Committee

Financial news for PCRX dated on 2017-11-14: Pacira Announces FDA Advisory Committee Meeting to Review sNDA for EXPAREL as a Nerve Block for Regional Analgesia

Financial news for PCRX dated on 2017-11-14: Pacira Reports FDA Advisory Committee Meeting to Review sNDA for EXPAREL Tentatively Scheduled For Feb. 14-15, 2018

Financial news for PCRX dated on 2017-11-09: BMO Capital Maintains Market Perform on Pacira Pharmaceuticals, Raises Price Target to \$39.00

Financial news for PCRX dated on 2017-11-09: H.C. Wainwright Assumes Pacira Pharmaceuticals at Buy, Announces price target \$52.00

Financial news for PCRX dated on 2017-11-09: 57 Biggest Movers From Yesterday

Financial news for PCRX dated on 2017-11-08: Pacira Pharmaceuticals Lowers FY17 EXPAREL Net Product Sales From \$290-\$310M To \$280-\$285M

Financial news for PCRX dated on 2017-11-08: Pacira Pharmaceuticals Reports Q3 EPS \$0.11 vs \$(0.06) Est., Sales \$67.3M vs \$70M Est.

Financial news for PCRX dated on 2017-10-30: Benzinga's Top Upgrades, Downgrades For October 30, 2017

Financial news for PCRX dated on 2017-10-30: Canaccord Genuity Downgrades Pacira Pharmaceuticals to Hold

Financial news for PCRX dated on 2017-10-26: 22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency

Financial news for PCRX dated on 2017-10-26: Pres Trump Implies Top Priority Is Removing Fentanyl From Market

Financial news for PCRX dated on 2017-10-26: Watching Opioid-Related Stocks As Pres Trump Declares America's Opioid Epidemic A National Public Health Emergency

Financial news for PCRX dated on 2017-10-26: Benzinga's Top Upgrades, Downgrades For October 26, 2017

Financial news for PCRX dated on 2017-10-26: The Market In 5 Minutes: Twitter Beats Estimates, WSJ Goes After Morningstar's Rating System

Financial news for PCRX dated on 2017-10-26: Janney Capital Downgrades Pacira Pharmaceuticals to Sell

Financial news for PCRX dated on 2017-10-25: Pacira Pharma Announces up to a \$25M Investment in TELA Bio

Financial news for PCRX dated on 2017-10-18: Pacira Pharma Reports FDA Acceptance Of sNDA For EXPAREL As Nerve Block To Produce Regional Analgesia

Financial news for PCRX dated on 2017-10-12: Watch These 7 Huge Call Purchases In Thursday Trade

Financial news for PCRX dated on 2017-10-11: Benzinga's Option Alert Recap From October 11

Financial news for PCRX dated on 2017-10-11: Pacira Pharma Option Alert: Nov 17 \$35 Calls Sweep (25) at the Bid: 521 @ \$2.4 vs 231 OI; Ref=\$34.375

Financial news for PCRX dated on 2017-09-28: Goldman Sachs Initiates Coverage On Pacira Pharmaceuticals with Neutral Rating, Announces \$41.00 Price Target

Financial news for PCRX dated on 2017-09-19: Benzinga's Option Alert Recap From

September 19

Financial news for PCRX dated on 2017-09-19: Pacira Pharma Option Alert: Nov 17 \$40 Calls at the Ask: 500 @ \$1.9 vs 97 OI; Ref=\$35.85

Financial news for PCRX dated on 2017-09-07: Oppenheimer Initiates Coverage On Pacira Pharmaceuticals with Market Perform Rating

Financial news for PCRX dated on 2017-09-06: Watch These 3 Huge Call Purchases In Wednesday Trade

Financial news for PCRX dated on 2017-09-05: Benzinga's Option Alert Recap From September 5

Financial news for PCRX dated on 2017-09-05: Pacira Pharma Option Alert: Nov 17 \$45 Calls at the Ask: 1300 @ \$1.5 vs 37 OI; Ref=\$37.25 Signals 11:44:22am

Financial news for PCRX dated on 2017-08-22: 13G Filing From Point72 Shows 5% Stake In Pacira Pharmaceuticals

Financial news for PCRX dated on 2017-08-22: Needham Initiates Coverage On Pacira Pharmaceuticals with Buy Rating, Announces \$55.00 Price Target

Financial news for PCRX dated on 2017-08-21: Benzinga's Top Upgrades, Downgrades For August 21, 2017

Financial news for PCRX dated on 2017-08-21: Janney Capital Upgrades Pacira Pharmaceuticals to Neutral

Financial news for PCRX dated on 2017-08-14: Healthcor Management Reports 6.2% Passive Stake In Pacira Pharmaceuticals -13G

Financial news for PCRX dated on 2017-08-02: Pacira Pharmaceuticals Sees FY17 Sales \$290-\$310M vs \$304M Est.

Financial news for PCRX dated on 2017-08-02: Pacira Pharmaceuticals Reports Q2 Adj. EPS \$(0.11) vs \$(0.03) Est., Sales \$70.9M vs \$73.6M Est.

Financial news for PCRX dated on 2017-07-26: Pacira Reports Publication of Phase 4 Study of EXPAREL in Patients Undergoing Total Knee Replacement in The Journal of Arthroplasty, Showed 78% Decrease In Opioid Consumption And Better Pain Control With Infiltration of EXPAREL Plus bupivacaine vs bupiva

Financial news for PCRX dated on 2017-07-25: Mid-Afternoon Market Update: Crude Oil Up 3%; Seagate Shares Drop After Q4 Miss

Financial news for PCRX dated on 2017-07-25: 20 Biggest Mid-Day Losers For Tuesday

Financial news for PCRX dated on 2017-07-25: Mid-Day Market Update: Dow Rises Over 100 Points; Team Shares Plummet

Financial news for PCRX dated on 2017-07-25: Pacira Pharma Shares Down 8.4% Pre-Market Following Disappointing Lower Extremity Study Results From Phase 3 Study Of EXPAREL

Financial news for PCRX dated on 2017-07-25: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for PCRX dated on 2017-07-25: Pacira Phase 3 Results For EXPAREL Demonstrated Statistical Significance For Both Primary And Secondary Endpoints In Upper Extremity Study But Did Not For The Lower Extremity Study, Timing For Resubmission Of Supplemental NDA Remains On Track

Financial news for PCRX dated on 2017-06-29: 8-K From Pacira Pharma Shows Company To Discontinue All Production Of DepoCyt Due To 'Persistent Technical Issues' Specific To The Manufacturing Process

Financial news for PCRX dated on 2017-05-23: Pacira Pharma Announces Pres James Scibetta Resigned; Says Does Not Intend to Name Successor

Financial news for PCRX dated on 2017-05-04: Pacira Pharmaceuticals Reports Q1 EPS \$0.15 vs \$(0.04) Est., Sales \$69.3M vs \$70.2M Est.

Financial news for PCRX dated on 2017-04-17: Partner Fund Management Reports 5.9% Stake in Pacira Pharmaceuticals in 13G

Financial news for PCRX dated on 2017-04-13: RBC Capital Initiates Coverage On Pacira Pharmaceuticals with Outperform Rating, Announces \$58.00 Price Target



Financial news for PCRX dated on 2017-03-23: Trinity Health, Pacira Pharmaceuticals Announce Collaboration to Decrease Opioid Use

Financial news for PCRX dated on 2017-03-22: Wedbush Reiterates Outperform On Pacira Pharmaceuticals, Maintains \$89 Price Target

Financial news for PCRX dated on 2017-03-20: Leerink Presents: Your 2017 Biopharma Catalyst Tracker

Financial news for PCRX dated on 2017-03-14: Pacira Pharmaceuticals Reports Co-Primary Endpoints Met Statistical Significance

Financial news for PCRX dated on 2017-03-01: 20 Biggest Mid-Day Gainers For Wednesday

Financial news for PCRX dated on 2017-03-01: Pacira Pharmaceuticals Reports Q4 EPS \$0.10 vs. \$0.01 Est., \$72.9M vs. \$73M Est.

Financial news for PCRX dated on 2017-03-01: Pacira Pharma Reports Q4 Adj. EPS \$0.09 vs \$0.01 Est., Sales \$72.9M vs \$73M Est.

Financial news for PCRX dated on 2017-02-22: Canaccord Genuity Initiates Coverage On Pacira Pharmaceuticals to Buy

Financial news for PCRX dated on 2017-02-07: Your Guide To 2017's Emerging Pharmaceuticals Catalysts

Financial news for PCRX dated on 2017-01-25: Hearing Cowen Out Cautious On Pacira Pharmaceuticals

Financial news for PCRX dated on 2017-01-25: Pacira Pharma Reports Collaboration with DePuy Synthes for Supporting of Promotion, Education, Training of EXPAREL in Orthopedics

Financial news for PCRX dated on 2017-01-06: Mid-Afternoon Market Update: AZZ Drops On Weak Q3 Results; Stemline Shares Spike Higher

Financial news for PCRX dated on 2017-01-06: 15 Biggest Mid-Day Gainers For Friday

Financial news for PCRX dated on 2017-01-06: Mid-Day Market Update: Dow Gains 50 Points; Ruby Tuesday Shares Fall Following Q2 Results

Financial news for PCRX dated on 2017-01-06: Pacira Pharma Q4 Revenue \$72.9M vs \$72.6M Est

Financial news for PCRX dated on 2017-01-03: 13 Emerging Biotechs With Catalysts In 2017

Financial news for PCRX dated on 2017-01-03: Benzinga's Top Upgrades, Downgrades For January 3, 2017

Financial news for PCRX dated on 2017-01-03: H.C. Wainwright Initiates Coverage On Pacira Pharmaceuticals at Buy, Announces price target \$43.00

Financial news for PCRX dated on 2016-12-02: Benzinga's Top Initiations

Financial news for PCRX dated on 2016-12-02: Janney Capital Initiates Coverage On Pacira Pharmaceuticals at Neutral, Announces \$31.00 Target

Financial news for PCRX dated on 2016-12-01: Goldman Sachs Initiates Coverage On Pacira Pharmaceuticals at Neutral, Announces \$36.00 Target

Financial news for PCRX dated on 2016-11-29: Pacira Pharmaceuticals, GeneAlign Report Partnership to Develop Low-Opioid Pain Management Protocols for Postsurgical Patients at High Risk of Addiction

Financial news for PCRX dated on 2016-11-17: Jefferies London Health Care Conference Continues Today

Financial news for PCRX dated on 2016-11-02: Pacira Sees FY16 Rev. \$263-\$268M vs. Est. \$277M

Financial news for PCRX dated on 2016-11-02: Pacira Pharmaceuticals Reports Q3 EPS \$0.22 vs. Est. \$(0.02), Rev. \$68.4M vs. Est. \$67M

Financial news for PCRX dated on 2016-10-27: Benzinga's Top Upgrades

Financial news for PCRX dated on 2016-10-27: BMO Capital Upgrades Pacira Pharmaceuticals, Inc. - Common Stock to Market Perform, Lowers to \$35.00

Financial news for PCRX dated on 2016-10-07: Brean Capital Assumes Pacira Pharmaceuticals at Hold

Financial news for PCRX dated on 2016-09-21: Mid-Afternoon Market Update: Dow Surges 125 Points; FedEx Shares Jump Following Upbeat Earnings

Financial news for PCRX dated on 2016-09-21: 12 Biggest Mid-Day Losers For Wednesday

Financial news for PCRX dated on 2016-09-21: Mid-Day Market Update: Crude Oil Up 2.75%; Mast Therapeutics Shares Drop After Sickie Cell Drug Phase 3 Trial Fail

Financial news for PCRX dated on 2016-09-21: Pacira Pharma Reports Launch of EXPAREL for Treatment of Pain Following Oral, Maxillofacial Procedures

Financial news for PCRX dated on 2016-09-21: Mid-Morning Market Update: Markets Open Higher; General Mills Earnings Top Views

Financial news for PCRX dated on 2016-09-07: Benzinga's Top Initiations

Financial news for PCRX dated on 2016-09-07: Cowen & Company Initiates Coverage on Pacira Pharmaceuticals at Market Perform

Financial news for PCRX dated on 2016-08-04: Major Averages Close Thursday's Session Mostly Unchanged

Financial news for PCRX dated on 2016-08-04: 20 Biggest Mid-Day Gainers For Thursday

Financial news for PCRX dated on 2016-08-04: Pacira Sees FY16 EXPAREL Product Sales \$270M-\$280M vs \$282.5M Est.

Financial news for PCRX dated on 2016-08-04: Pacira Pharma Reports Q2 Adj. EPS \$0.19 vs \$0.23 in Same Qtr. Last Year, Sales \$65.8M vs \$67.4M Est.

Financial news for PCRX dated on 2016-07-01: Benzinga's Volume Movers

Financial news for PCRX dated on 2016-07-01: Exparel Concerns Weigh On Pacira Pharma, Brean Moves To Sidelines

Financial news for PCRX dated on 2016-07-01: Pacira Pharmaceuticals To Terminate Agreement With CrossLink, Will Incur Termination Fee Of \$7.3M

Financial news for PCRX dated on 2016-07-01: Brean Capital Downgrades Pacira Pharmaceuticals to Hold

Financial news for PCRX dated on 2016-06-30: Pacira Pharmaceuticals Sells off to Low of \$32.71 on Vol

Financial news for PCRX dated on 2016-06-29: Pacira Shares Tumble Following BMO's New Underperform Rating

Financial news for PCRX dated on 2016-06-29: BMO Capital Initiates Coverage on Pacira Pharmaceuticals at Underperform

Financial news for PCRX dated on 2016-05-02: Pacira Pharma Reports Q1 Adj. EPS \$0.15 vs \$0.08 Est., Sales \$63.8M vs \$67M Est.

Financial news for PCRX dated on 2016-04-19: Mizuho: Pacira Pharma Has 'Forever' Potential, Stock Is A Buy

Financial news for PCRX dated on 2016-04-19: Pacira Pharma Names Charles Reinhart CFO

Financial news for PCRX dated on 2016-04-19: Mizuho Securities Initiates Coverage on Pacira Pharmaceuticals at Buy

Financial news for PCRX dated on 2016-04-18: Option Alert: PCRX Aug16 75.0 Puts Sweep: 550 @ ASK \$14.70: 556 traded vs 256 OI: Earnings 5/2 Before Open \$64.86 Ref

Financial news for PCRX dated on 2016-04-05: Pacira Pharmaceuticals Names Robert Weiland as Chief Commercial Officer

Financial news for PCRX dated on 2016-02-26: Brean Capital Maintains Buy on Pacira Pharmaceuticals, Lowers PT to \$75.00

Financial news for PCRX dated on 2016-02-25: Pacira Pharmaceuticals Reports Q4 EPS \$0.22 vs. Est. \$0.27, Rev. \$69.3M vs. Est. \$68.4M

Financial news for PCRX dated on 2016-01-29: Pacira Pharma Shares Spike to High of \$60; May be Attributed to BofA Upgrade

Financial news for PCRX dated on 2016-01-28: Mid-Afternoon Market Update: Dow Rises Over 100 Points; eBay Shares Drop On Disappointing Outlook

Financial news for PCRX dated on 2016-01-07: Pacira Pharma Sees Q4 Total Sales \$69.4M vs \$67.44M Est., FY15 Total Sales \$249M vs \$247M Est.

Financial news for PCRX dated on 2016-01-05: Benzinga's Top Initiations

Financial news for PCRX dated on 2016-01-05: CORRECTION: JMP Securities Initiates Coverage on Pacira Pharmaceuticals at Market Outperform, Announces \$92.00 PT

Financial news for PCRX dated on 2016-01-05: JMP Securities Initiates Coverage on Pacira Pharmaceuticals at Market Outperform, Announces \$92.00 PT

Financial news for PCRX dated on 2016-01-02: Every Biotech Catalyst Wedbush Is Watching In 2016

Financial news for PCRX dated on 2015-12-15: Mid-Day Market Update: Kennametal Drops On Lowered Guidance; Lumber Liquidators Shares Jump

Financial news for PCRX dated on 2015-12-15: Benzinga's Volume Movers

Financial news for PCRX dated on 2015-12-15: Mid-Morning Market Update: Markets Open Higher; FactSet Misses Q1 Views

Financial news for PCRX dated on 2015-12-15: Pacira Pharmaceuticals Achieves Favorable Resolution With FDA; Reaffirms Broad Indication for EXPAREL

Financial news for PCRX dated on 2015-11-25: Mid-Morning Market Update: Markets Edge Higher; Deere Profit Tops Views

Financial news for PCRX dated on 2015-10-27: Mid-Afternoon Market Update: GrubHub Drops On Earnings Miss; Pacira Pharmaceuticals Shares Gain

Financial news for PCRX dated on 2015-10-27: Mid-Day Market Update: Heidrick & Struggles Jumps On Strong Results; Roadrunner Transportation Systems Shares Decline

Financial news for PCRX dated on 2015-10-27: Mid-Morning Market Update: Markets Down; Ford Earnings Miss Views

Financial news for PCRX dated on 2015-10-27: Morning Market Gainers

Financial news for PCRX dated on 2015-10-27: Benzinga's Top #PreMarket Gainers

Financial news for PCRX dated on 2015-10-27: Pacira Pharma Reports Q3 Sales \$62.2M vs \$60M Est., Adj. EPS \$0.32 vs \$0.15 Est.

Financial news for PCRX dated on 2015-10-21: Biotech Names Like Horizon, Pacira, Akorn, Shire, Mallinckrodt Volatile On Citron Report & Subsequent Valeant Pharma. Press Release

Financial news for PCRX dated on 2015-10-20: Pacira Pharmaceuticals Names James S. Scibetta as President

Financial news for PCRX dated on 2015-10-19: Shares of Pacira Pharma Up ~8%; Hearing Law360 Reporting FDA Has Removed Warning Letter Related to Facility

Financial news for PCRX dated on 2015-09-29: 5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm

Financial news for PCRX dated on 2015-09-29: Nomura Lists AGN, VRX, PCRX, ENDP, & PDHL As Top Picks, Says M&A Remains Value Driver & More Consolidation

Financial news for PCRX dated on 2015-09-23: Wedbush Thinks Pacira Pharma Is Worth \$106 On Exparel Sales

Financial news for PCRX dated on 2015-09-23: Morning Market Losers

Financial news for PCRX dated on 2015-09-08: Pacira Pharmaceuticals Seeks Court Injunction to Defend its Rights to Share Information about EXPAREL Consistent with its FDA-Approved Indication

Financial news for PCRX dated on 2015-08-19: Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, as SVP and Chief Medical Officer

Financial news for PCRX dated on 2015-07-31: Bank of America Upgrades Pacira Pharmaceuticals to Neutral

Financial news for PCRX dated on 2015-07-15: Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results for Controlling Postsurgical Pain in Dogs

Financial news for PCRX dated on 2015-07-14: Aratana Therapeutics Announces Positive Pivotal Results for AT-003

Financial news for PCRX dated on 2015-06-19: Leerink Swann Initiates Pacira Pharmaceuticals With Market Perform

Financial news for PCRX dated on 2015-06-19: Benzinga's Top Initiations

Financial news for PCRX dated on 2015-06-19: Leerink Swann Initiates Coverage on Pacira Pharmaceuticals at Market Perform, Announces \$86.00 PT

Financial news for PCRX dated on 2015-05-29: Who's The Next Big Pharma Acquisition?

Financial news for PCRX dated on 2015-05-28: Pacira Pharmaceuticals Announces Completion of End-of-Review Process with FDA Regarding EXPAREL sNDA for Nerve Block

Financial news for PCRX dated on 2015-05-19: Pacira Announces New Data Supporting Clinical and Pharmacoeconomic Utility of EXPAREL in Patients Undergoing Various Surgical Procedures

Financial news for PCRX dated on 2015-04-30: Morning Market Losers

Financial news for PCRX dated on 2015-04-30: Pacira Pharma Q1 EPS \$0.23 vs \$0.20 est, Revenue \$58.3M vs \$61.1M est

Financial news for PCRX dated on 2015-04-16: Morning Market Losers

Financial news for PCRX dated on 2015-04-16: Benzinga's Top #PreMarket Losers

Financial news for PCRX dated on 2015-04-16: Pacira Receives Subpoena from US DoJ

Financial news for PCRX dated on 2015-04-10: Pacira Reports New Data on Health Economic Benefits of EXPAREL for Post Surgery Pain Control Proceeding Complete Knee Replacement Surgery

Financial news for PCRX dated on 2015-03-26: Pacira Says Data Reinforce Benefits of EXPAREL for Postsurgical Pain Control

Financial news for PCRX dated on 2015-03-26: Pacira Announces Data Reinforcing Benefits of EXPAREL for Postsurgical Pain Control Following Total Hip and Knee Replacement Surgery

Financial news for PCRX dated on 2015-03-25: Wedbush Securities Believes SH Data Bodes Well For Pacira Pharmaceuticals

Financial news for PCRX dated on 2015-03-02: Morning Market Losers

Financial news for PCRX dated on 2015-03-02: Pacira Pharmaceuticals Shares Fall 14% Premarket on CRL from FDA for EXPAREL sNDA

Financial news for PCRX dated on 2015-03-02: Benzinga's Top #PreMarket Losers

Financial news for PCRX dated on 2015-03-02: Pacira Receives CRL from FDA for sNDA Seeking Approval of EXPAREL Use in Nerve Block to Provide Postsurgical Analgesia

Financial news for PCRX dated on 2015-02-26: Bank of America Downgrades Pacira Pharmaceuticals to Underperform

Financial news for PCRX dated on 2015-02-25: JPM Securities Picks Through Biotech News For Winners

Financial news for PCRX dated on 2015-02-24: Pacira Pharma Q4 EPS \$0.35 vs \$0.27, Revenue \$61.8M vs \$62.1M

Financial news for PCRX dated on 2015-02-17: 3 Niche ETFs Breaking Out

Financial news for PCRX dated on 2015-02-11: US Stock Futures Edge Lower Ahead Of Earnings

Financial news for PCRX dated on 2015-02-11: Pacira Pharmaceuticals Announces Resolution of Warning Letter with FDA's OPDP

Financial news for PCRX dated on 2015-02-04: Biotech Breakout Alert: Pacira Pharmaceuticals Could Be On The Cusp

Financial news for PCRX dated on 2015-02-01: Biotech Breakdown: Market Breaks...Gilead, Kite Pharma & Biogen Idec Worth Watching

Financial news for PCRX dated on 2015-01-08: Pacira Preliminary Q4 Revenue \$81.8M vs \$60.44M

Financial news for PCRX dated on 2015-01-02: New Biotech ETF From ALPS

Financial news for PCRX dated on 2014-12-16: Aratana Therapeutics Initiates Pivotal Study For AT-003

Financial news for PCRX dated on 2014-12-12: Pacira Pharma Reports Changes to EXPAREL Label, Indication Not Affected

Financial news for PCRX dated on 2014-11-06: Pacira Pharmaceuticals Inc. Announces New Data on the Use of EXPAREL to Treat Postsurgical Pain Following Total Knee Arthroplasty

Financial news for PCRX dated on 2014-10-31: Bank of America Downgrades Pacira Pharmaceuticals, Inc. to Neutral

Financial news for PCRX dated on 2014-10-30: Pacira Pharmaceuticals, Inc. Reports Q3 EPS of \$0.14 vs \$0.10 Est; Revenue of \$52.0M vs \$52.20M Est

Financial news for PCRX dated on 2014-10-27: New Study Correlates Use Of EXPAREL For Postsurgical Pain Management With Significant Reductions In Opioid Related Adverse Events

Financial news for PCRX dated on 2014-10-20: Bank Of America Q3 Small & Mid-Cap Biotech Preview

Financial news for PCRX dated on 2014-10-15: Michael Boyd Of The Boyd Group On CNBC Speaking On Ebola Impact To Airlines Says "This Is A Scare That Will Evaporate"

Financial news for PCRX dated on 2014-10-13: UPDATE: Pacira Pharma Sets Target PDUFA Date for EXPAREL as Mar. 5, 2015

Financial news for PCRX dated on 2014-10-13: Pacira Pharma Offers Added Data Support Safety of EXPAREL in Peripheral Nerve Block

Financial news for PCRX dated on 2014-10-08: Bank Of America Sees Significant Manufacturing Capacity Expansions Underway For Pacira Pharmaceuticals

Financial news for PCRX dated on 2014-09-25: NASDAQ Dips 1.5%; HB Fuller Shares Decline On Downbeat Results

Financial news for PCRX dated on 2014-09-25: Markets Tumble; Scholastic Posts Wider Fiscal-First Quarter Loss

Financial news for PCRX dated on 2014-09-25: Morning Market Losers

Financial news for PCRX dated on 2014-09-25: Benzinga's Top #PreMarket Losers

Financial news for PCRX dated on 2014-09-25: US Stock Futures Flat Ahead Of Jobless Claims, Durable-Goods Orders Data

Financial news for PCRX dated on 2014-09-25: Pacira Pharmaceuticals, Inc. Announces Receipt of FDA Warning Letter

Financial news for PCRX dated on 2014-07-31: Pacira Pharmaceuticals, Inc. Reports Q2 EPS of \$0.04 vs \$(0.20) Est; Revenue of \$47.20M vs \$43.17M Est

Financial news for PCRX dated on 2014-07-17: UPDATE: Bank Of America Reiterates On Pacira Pharmaceuticals On Positive Survey Results

Financial news for PCRX dated on 2014-06-27: Canaccord Genuity Initiates Coverage on Pacira Pharmaceuticals, Inc. at Buy, Announces \$109.00 PT

Financial news for PCRX dated on 2014-06-26: Pacira Pharmaceuticals Says Multi-Study Analysis Published in Journal of Pain Research Reinforces Value of Exparel-Based Regimen

Financial news for PCRX dated on 2014-06-23: 3 Hot Biotech Stocks Hitting Highs

Financial news for PCRX dated on 2014-06-17: UPDATE: JMP Securities Initiates Coverage On Pacira Pharmaceuticals

Financial news for PCRX dated on 2014-06-17: JMP Securities Initiates Coverage on Pacira Pharmaceuticals, Inc. at Market Outperform

Financial news for PCRX dated on 2014-06-02: Goldman Sachs Initiates Coverage on Pacira Pharmaceuticals, Inc. at Buy, Announces \$93.00 PT

Financial news for PCRX dated on 2014-05-07: Pacira Pharmaceuticals Submits sNDA to FDA for EXPAREL Nerve Block Indication

Financial news for PCRX dated on 2014-05-06: Sohn Conference Moves Markets Once Again

Financial news for PCRX dated on 2014-05-05: Gordon: PT on PCRX is \$140

Financial news for PCRX dated on 2014-05-05: Gordon: Likes Pacira Pharma

Financial news for PCRX dated on 2014-05-01: Pacira Pharmaceuticals Reports Q1 EPS of \$(0.34) vs \$(0.32) Est; Revenue of \$36.70M vs \$35.40M Est

Financial news for PCRX dated on 2014-04-21: Jefferies Initiates Coverage on Pacira Pharmaceuticals, Inc. at Buy, Announces \$81.00 PT

Financial news for PCRX dated on 2014-04-15: Pacira Pharma Reports Grants of Inducement Stock Options Related to NASDAQ Listing Rule 5635(c)(4)

Financial news for PCRX dated on 2014-04-09: Benzinga's Volume Movers

Financial news for PCRX dated on 2014-04-08: Pacira Pharmaceuticals Prices 1.6M Share Offering at \$64.00/Share

Financial news for PCRX dated on 2014-04-07: Pacira Pharma Announces \$100M Offering of Common Stock

Financial news for PCRX dated on 2014-04-07: Pacira Pharma Files Automatic Mixed Securities Shelf

Financial news for PCRX dated on 2014-04-07: CorMedix Welcomes Additional Board Members

Financial news for PCRX dated on 2014-03-31: Mid-Morning Market Update: Markets Open Higher; UTi Worldwide Reports Q4 Loss

Financial news for PCRX dated on 2014-03-31: Pacira Pharmaceuticals Announces FDA Approves Additional Manufacturing Suite for EXPAREL

Financial news for PCRX dated on 2014-01-07: Pacira Says Exparel Multimodal Analgesia Reduced Opioid Use, Says Data Reinforces Findings from IMPROVE Trial

Financial news for PCRX dated on 2013-12-05: Pacira Pharma Submits Prior Approval Supplement for Additional EXPAREL Manufacturing Suite, Expecting PDUFA Date in Early April 2014

Financial news for PCRX dated on 2013-10-01: Shares of Pacira Pharma Breaking Out Over Resistance Level at \$49, Charged Through \$50, \$51 Levels, Now Up 6+%; Jefferies Earlier Raised Price Target from \$44 to \$58

Financial news for PCRX dated on 2013-10-01: Jefferies Maintains Buy on Pacira Pharmaceuticals, Inc., Raises PT to \$58.00

Financial news for PCRX dated on 2013-09-20: Barclays Maintains Overweight on Pacira Pharmaceuticals, Inc., Raises PT to \$43.00

Financial news for PCRX dated on 2013-08-07: UPDATE: Piper Jaffray Downgrades Pacira Pharmaceuticals Following 2Q13 Net Loss

Financial news for PCRX dated on 2013-08-06: Piper Jaffray Downgrades Pacira Pharmaceuticals, Inc. to Neutral, Raises PT to \$38.00

Financial news for PCRX dated on 2013-08-01: Pacira Pharma Shares Sink as Co. Announces EXPAREL Phase 3 Trial Does Not Meet Primary Endpoint

Financial news for PCRX dated on 2013-07-18: New Study Shows Significant Reduction in Opioids, Length of Hospital Stay and Cost of Care for Patients Receiving EXPAREL(r) Made By Pacira

Financial news for PCRX dated on 2013-07-01: Stocks to Watch for July 01, 2013

Financial news for PCRX dated on 2013-05-29: Pacira Pharmaceutical's EXPAREL Shows Positive Safety and Efficacy Results

Financial news for PCRX dated on 2013-05-08: Pacira Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.71) vs \$(0.41) Est; Revenue of \$11.60M vs \$13.22M Est

Financial news for PCRX dated on 2013-05-06: Two New Studies Support Use of EXPAREL via Infiltration Into the Transversus Abdominis Plane for Postsurgical Pain Control

Financial news for PCRX dated on 2013-03-21: MPM Bioventures IV Cuts Stake in Pacira Pharma from 10.1% Stake to 4.2%

Financial news for PCRX dated on 2013-03-18: Mid-Day Market Update: Markets Trim Losses, Incyte Drops

Financial news for PCRX dated on 2013-03-13: Pacira Pharmaceuticals Moves Lower, May be Attributed to Seeking Alpha Article

Financial news for PCRX dated on 2013-03-11: UPDATE: Jefferies Raises PT to \$32 on Pacira Pharmaceuticals on Exparel Launch Momentum

Financial news for PCRX dated on 2013-03-11: Jefferies Maintains Buy on Pacira Pharmaceuticals, Inc., Raises PT to \$32.00

Financial news for PCRX dated on 2013-03-08: UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Pacira Pharmaceuticals on Strong Momentum

Financial news for PCRX dated on 2013-03-07: UPDATE: Wedbush Raises PT to \$32 on Pacira Pharmaceuticals on Long-Term Outlook

Financial news for PCRX dated on 2013-03-07: Wedbush Maintains Outperform on Pacira Pharmaceuticals, Inc., Raises PT to \$32.00

Financial news for PCRX dated on 2013-03-07: Pacira Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.50) vs \$(0.42) Est; Revenue of \$10.45M vs \$9.83M Est

Financial news for PCRX dated on 2013-02-01: NASDAQ to Cancel Trades in Pacira Pharma Between 2:38-2:39PM EST

Financial news for PCRX dated on 2013-01-28: UPDATE: Piper Jaffray Raises PT to \$27 on Pacira Pharmaceuticals on Strong Exparel Data Points

Financial news for PCRX dated on 2013-01-28: Piper Jaffray Maintains Overweight on Pacira Pharmaceuticals, Inc., Raises PT to \$27.00

Financial news for PCRX dated on 2013-01-18: UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Pacira Pharmaceuticals

Financial news for PCRX dated on 2013-01-18: Jefferies Maintains Buy on Pacira Pharmaceuticals, Inc., Raises PT to \$24.00

Financial news for PCRX dated on 2013-01-17: Pacira Pharma Prices \$110M Private Offering of Convertible Notes

Financial news for PCRX dated on 2013-01-15: Pacira Pharmaceuticals Announces Proposed Offering of \$100 Million of Convertible Senior Notes

Financial news for PCRX dated on 2012-11-01: Pacira Pharmaceuticals Reports Q3 EPS \$-0.49 vs \$-0.44 Est; Revenues \$8.49M vs \$7.85M Est

Financial news for PCRX dated on 2012-10-08: From Earlier: Pacira Says Statistical Significance Seen at Primary Endpoints

Financial news for PCRX dated on 2012-09-11: Wedbush Securities Maintains Pacira Pharmaceuticals at Outperform, Raises PT from \$18 to \$23

Financial news for PCRX dated on 2012-09-05: Pacira Pharmaceuticals Reports Reduced Pain, Opioid Use, and Opioid-Related Adverse Events in Patients Receiving EXPAREL

Financial news for PCRX dated on 2012-08-14: Barclays Maintains Pacira Pharmaceuticals at Overweight, Raises PT from \$12 to \$19

Financial news for PCRX dated on 2012-08-10: Jefferies & Company Maintains Pacira Pharmaceuticals at Buy, Raises PT from \$18 to \$22

Financial news for PCRX dated on 2012-06-20: Wedbush Securities Raises PT on Pacira Pharmaceuticals from \$15 to \$18, Maintains Outperform

Financial news for PCRX dated on 2012-04-25: Pacira Pharmaceuticals Announces Full Exercise of Overallotment Option by Underwriters

Financial news for PCRX dated on 2012-04-23: Wedbush Securities Maintains Pacira Pharmaceuticals at Outperform, Lowers PT from \$18 to \$15

Financial news for PCRX dated on 2012-04-12: Pacira Pharmaceuticals Prices Public Offering of 6M Shares Common Stock at \$9.75/Share

Financial news for PCRX dated on 2012-04-11: Pacira Pharma Reports Proposed Offering of Stock

Financial news for PCRX dated on 2012-04-09: Wedbush Securities Maintains Pacira Pharmaceuticals at Outperform, Raises PT from \$16 to \$18

Financial news for PCRX dated on 2012-04-09: Pacira Pharmaceuticals Announces Commercial Availability of EXPAREL

Financial news for PCRX dated on 2012-03-28: UPDATE: Piper Jaffray Raises Pacira Pharmaceuticals' PT

Financial news for PCRX dated on 2012-03-28: Piper Jaffray Maintains Pacira Pharmaceuticals at Overweight, Raises PT from \$11 to \$15

Financial news for PCRX dated on 2012-03-27: Pacira Pharma Registers for \$150M Mixed Securities Shelf Offering

Financial news for PCRX dated on 2012-03-27: Earnings Scheduled For March 27

Financial news for PCRX dated on 2012-01-09: Pacira Pharmaceuticals Announces EXPAREL Expected to be Commercially Available in April 2012

Financial news for PCRX dated on 2011-12-19: Pacira Pharmaceuticals Announces Results from EXPAREL Pivotal Trial Published in Diseases of the Colon & Rectum

Financial news for PCRX dated on 2011-11-28: Piper Jaffray Lowers PT on Pacira Pharmaceuticals to \$11

Financial news for PCRX dated on 2011-11-22: Pacira Pharmaceuticals, Inc. Announces Completion of Follow-on Offering of Common Stock and Exercise of Over-Allotment Option

Financial news for PCRX dated on 2011-11-21: How Will Congress' Budget Cuts Affect Health Care?

Financial news for PCRX dated on 2011-11-16: Pacira Pharmaceuticals Announces Pricing of Follow-On Offering; 7M Shares at \$6.50/Share

Financial news for PCRX dated on 2011-10-31: Benzinga's Top Pre-Market Gainers

Financial news for PCRX dated on 2011-10-31: Financial Breakfast: Morning News Summary for October 31, 2011

Financial news for PCRX dated on 2011-10-31: A Peek Into The Market Before The Trading Starts

Financial news for PCRX dated on 2011-10-31: Pacira Pharmaceuticals, Inc. Announces U.S. FDA Approval of EXPAREL For Postsurgical Pain Management

Financial news for PCRX dated on 2011-10-19: Pacira Pharmaceuticals Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL Compared to Bupivacaine HCl

Financial news for PCRX dated on 2011-10-12: Pacira Pharmaceuticals Hopes to Avoid Pain with Exparel PDUFA

Financial news for PCRX dated on 2011-09-26: Pacira Pharmaceuticals Announces Efficacy and Safety of EXPAREL Highlighted at "Hot Topics in Plastic Surgery" Panel

Financial news for PCRX dated on 2011-09-06: Top Narrow Based Indexes For September 6

Financial news for PCRX dated on 2011-09-06: Pacira Pharmaceuticals Expands EXPAREL Commercial Team Infrastructure

Financial news for PCRX dated on 2011-06-15: Piper Jaffray Reiterates Rating, PT On PCRX

Financial news for PCRX dated on 2011-06-14: Morning Market Losers

Financial news for PCRX dated on 2011-06-14: Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL PDUFA Target Date by Three Months

Financial news for PCRX dated on 2011-04-28: Stocks we are watching on 4/28- AMZN, LVLTT, NFLX, BIDU, ORCL, YRCW, AMD, GS, POT, FCX, SNDK, IRE, AIB, CIGX, CTIC, AKAM, WFMI



Financial news for PCRX dated on 2011-02-15: Pacira Pharmaceuticals Highlights  
Additional Safety Data on EXPAREL for Postsurgical Pain Relief

Financial news for PCRX dated on 2011-02-03: Pacira Pharmaceuticals IPO Priced at \$7  
per Share